Applying New Data to Treatment Selection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.

Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.